항균제 내성 진단 시장 : 병원체별, 기술별, 지역별 전략과 동향 - 이그제큐티브 컨설턴트 가이드 첨부(2025-2029년)

Antimicrobial Resistance Diagnostic Markets, Strategies and Trends By Pathogen, By Technology, and By Region with Executive and Consultant Guides. 2025 To 2029

US $ 6,995 ￦ 10,198,000

PDF (Single User License)

PDF 보고서를 1명(One device)만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,495 ￦ 15,301,000

PDF (Five User License)

PDF 보고서를 동일 사업장의 5명(Five devices)까지 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 13,995 ￦ 20,404,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄는 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

보고서 개요

항균제 내성으로 인한 위협을 줄이기 위해 진단 약품이 주도권을 쥐고 있습니다. 새로운 항생제가 등장하기 전에 이러한 기술들이 문제를 해결할 수 있는가? 이 성장하는 시장을 선점하기 위해 유전자 염기서열 분석에 국한되지 않는 새로운 진단 기술이 개발되고 있습니다. 기술의 큰 그림을 보고 병원체 및 감염병을 진단하는 다양한 방법을 알기 쉽게 이해할 수 있도록 했습니다. 이 분야의 6가지 주요 병원체에 대한 기회를 파악하고 시장 예측을 작성했습니다. 이 분야에서 활약하는 크고 작은 30 이상의 기업을 프로파일링하고 있습니다.

최신 데이터를 이용하여 투자 판단과 밸류에이션을 할 수 있습니다.

세계의 항균제 내성 진단 시장에 대해 조사했으며, 시장의 개요와 병원체별, 기술별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.

목차

제1장 시장 가이드

제2장 서론과 시장의 정의

• 항균제 내성의 위협과 기회
• 기회의 정의
• 방법과 정보원
• 시점 : 헬스케어와 IVD 업계
• 진단비

제3장 역동적인 시장의 개요

• 시장 참여 조직
  • 학술연구기관
  • 진단 시험 개발자
  • 계측 기기 공급업체
  • 약품·시약 제조업체
  • 병리 공급업체
  • 독립계 임상 검사실
  • 공공 국립/지역 연구소
  • 병원 검사실
  • 임상 검사실
  • 감사 기관
  • 인증 기관
• 항균제 내성에 대해 이해
• 새로운 항생제와 기술로 변화하는 길
• AMR에서 진단의 중요한 역할

제4장 AMR 시장 기회

• AMR에서의 주요 대규모 시장 기회
• 진단 기술개발 기회

제5장 항생제 내성 진단의 최근 동향

제6장 주요 AMR 진단 기업

• 1928 Diagnostics
• Abbott Laboratories
• Accelerate Diagnostics
• ADT Biotech
• Beckman Coulter Diagnostics(Danaher)
• Becton, Dickinson and Company
• Binx Health
• bioMerieux Diagnostics
• Bio-Rad Laboratories, Inc.
• Cepheid(Danaher)
• Curetis(OpGen)
• Day Zero Diagnostics
• DeepUII Diagnostics
• DNAe
• Enzo Biochem
• Eurofins Scientific
• Fusion Genomics
• GeneFluidics
• Genetic Signatures
• Great Basin Scientific, Inc
• Hologic
• Hutman Diagnostics
• Inflammatix
• Linear Diagnostics
• Lumos Diagnostics
• MGI
• Millipore Sigma
• OpGen
• Pathogenomix
• Qiagen
• QuidelOrtho
• Revvity
• Roche Diagnostics
• Scope Fluidics
• SeLux Diagnostics
• Sherlock Biosciences
• Siemens Healthineers
• Sysmex
• Thermo Fisher Scientific
• Uniogen
• Vela Diagnostics
• Visby Medical

제7장 세계의 항균제 내성 진단 시장

• 국가별 세계 시장 개요
• 병원체별 세계 시장 - 개요
• 기술별 세계 시장 - 개요

제8장 세계의 항생제 내성 진단 시장 - 병원체별

• 약제 내성 폐렴구균-DRSP
• 약제 내성 캄필로박터-DRC
• 클로스트리듐·디피실 CD
• 메티실린 내성 황색 포도 구균(MRSA)
• 약제 내성 임균(DRNG)
• 약제 내성 살모넬라균-DRNTS

제9장 세계의 항생제 내성 진단 시장 - 기술별

• 미생물학 배양
• 면역측정
• PCR
• NGS
• 질량분석법
• 신속 검사와 POC(Point of Care)

제10장 AMR 진단의 향후 비전

제11장 부록

KSA

영문 목차

영문목차

Report Overview:

Diagnostics are leading the charge in reducing the threat posed by antimicrobial resistance. Will these technologies solve the problem before new antibiotics come along? New diagnostic technologies, beyond gene sequencing, are under development to capture this growing market. We have looked at the technology picture, giving you plain language understanding of the different ways pathogens, and infections, can be diagnosed. We have identified the 6 Key Large Pathogen Opportunities in this space and developed market forecasts. We profile over 30 companies, large and small, working in this area.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

Table of Contents

1. Market Guides

• 1.1. Antimicrobial Resistance - Strategic Situation Analysis
• 1.2. Guide for Executives and Business Development Staff
• 1.3. Guide for Management Consultants and Investment Advisors

2. Introduction and Market Definition

• 2.1. The Threat and Opportunity of Antimicrobial Resistance
• 2.2. Defining the Opportunity
  • 2.2.1. Revenue Market Size
• 2.3. Methods and Sources
  • 2.3.1. Methodology
  • 2.3.2. Sources
  • 2.3.3. Authors
• 2.4. Perspective: Healthcare and the IVD Industry
  • 2.4.1. Global Healthcare Spending
• 2.5. Spending on Diagnostics
  • 2.5.1. Important Role of Insurance for Diagnostics

3. Overview of a Dynamic Market

• 3.1. Players in a Dynamic Market
  • 3.1.1. Diagnostic Test Developer
  • 3.1.2. Instrumentation Supplier
  • 3.1.3. Chemical/Reagent Supplier
  • 3.1.4. Pathology Supplier
  • 3.1.5. Independent Clinical Laboratory
  • 3.1.6. Public National/regional Laboratory
  • 3.1.7. Hospital Laboratory
  • 3.1.8. Physicians Office Lab (POLS)
  • 3.1.9. Audit Body
  • 3.1.10. Certification Body
• 3.2. Understanding Antimicrobial Resistance
  • 3.2.1. What is Antimicrobial Resistance (AMR)
  • 3.2.2. Bacteria and Other Microbes
  • 3.2.3. The History of Antibiotics
  • 3.2.4. The Role of Animal Husbandry
  • 3.2.5. The Implications of Horizontal Transfer
  • 3.2.6. The Threat of AMR
• 3.3. The Changing Road to New Antibiotics & Technologies
• 3.4. The Key Role of Diagnostics in AMR

4. The Market Opportunity of AMR

• 4.1. The Key Large Market Opportunities in AMR
  • 4.1.1. Streptococcus Pneumoniae (DRSP)
  • 4.1.2. Campylobacter (DRC)
  • 4.1.3. Clostridium Difficile (CD)
  • 4.1.4. Staphylococcus aureus (MRSA)
  • 4.1.5. Neisseria gonorrhoeae (DRNG)
  • 4.1.6. Salmonella (DRNTS)
• 4.2. Diagnostic Technology Development Opportunities
  • 4.2.1. What's Wrong with Microbiology
  • 4.2.2. The Features Battleground of Infectious Disease Diagnostics
  • 4.2.3. Multiplex vs. POC/Rapid
  • 4.2.4. The Miracle of Genetics
  • 4.2.5. From Multiple Pathogens to All Pathogens - The Next Next Generation
  • 4.2.6. Gene Sequence Diagnostics WITHOUT the Sequencing
  • 4.2.7. Markers of Resistance
  • 4.2.8. What Happens to the Microbiology Lab?

5. Antibiotic Resistance Diagnostics Recent Developments

• 5.1. Antibiotic Resistance Recent Developments
  • 5.1.1. Importance of These Developments
  • 5.1.2. How to Use This Section
• 5.2. DeepUll Raises Euro-50M in Oversubscribed Round
• 5.3. BioMerieux Gets Clearance for ID/AST System
• 5.4. New antibiotics could treat 'super bugs'
• 5.5. Cepheid, Fleming Partner to Address AMR
• 5.6. Fuse Dx and Prompt Dx Funded for POC Tests
• 5.7. FDA Approval for Karius
• 5.8. Presymptom Health Develops Sepsis Test
• 5.9. Visby Medical to Develop STI and AMR MDx
• 5.10. Siemens Healthineers to Develop NGS-Based Sepsis Test
• 5.11. Researchers Developing POC Test for Detecting Risk SNPs
• 5.12. Curetis, FIND Extend AMR Research
• 5.13. Delve Bio to Develop Metagenomic Dx
• 5.14. BioMerieux, Oxford Nanopore Form ID Dx Pact
• 5.15. DnaNudge, Mylab Forge Dx Partnership
• 5.16. FDA Clears New bioMerieux Diagnostic System and Panel
• 5.17. Selux Diagnostics Phenotyping System Gets FDA Approval
• 5.18. New diagnostics to tackle drug resistant infections
• 5.19. Takara Bio USA, Inc. and BioExcel Diagnostics Partner for Infectious Disease Panels
• 5.20. Three companies join forces to tackle antimicrobial resistance (AMR)
• 5.21. T2 Biosystems Exercises BARDA Option
• 5.22. OpGen to Ramp up Use of Acuitas AMR Gene Panel
• 5.23. BD Partners With Pfizer, Wellcome to Study AMR Dx
• 5.24. Sepsis Test Developers Accelerate Plans
• 5.25. OpGen Receives FDA Clearance for AMR Panel
• 5.26. Visby Medical - Rapid Uptake of Handheld PCR Test for STIs
• 5.27. MicroGenDx, OrthoKey Clinic and OrthoKey Surgery
• 5.28. BioMerieux Receives CE Mark for Vitek Clinical Microbiology System
• 5.29. Hologic to Acquire Mobidiag
• 5.30. Campylobacter strains exchange genes
• 5.31. Disinfection spreads antimicrobial resistance
• 5.32. Molzym, Fraunhofer Developing Rapid Sepsis Dx
• 5.33. Illumina, IDbyDNA Build NGS-Based Respiratory Panel
• 5.34. Accelerate Diagnostics Expands AMR Testing
• 5.35. Rapid diagnostics linked to optimal antibiotics
• 5.36. Visby Medical Wins AMR Diagnostic Competition
• 5.37. DNAe Technology SARS-CoV-2 Sequences
• 5.38. Infections with foodborne bacteria becoming harder to treat
• 5.39. Dust is sharing antibiotic resistance genes

6. Key AMR Diagnostics Companies

• 6.1. 1928 Diagnostics
• 6.2. Abbott Laboratories
• 6.3. Accelerate Diagnostics
• 6.4. ADT Biotech
• 6.5. Beckman Coulter Diagnostics (Danaher)
• 6.6. Becton, Dickinson and Company
• 6.7. Binx Health
• 6.8. bioMerieux Diagnostics
• 6.9. Bio-Rad Laboratories, Inc.
• 6.10. Cepheid (Danaher)
• 6.11. Curetis (OpGen)
• 6.12. Day Zero Diagnostics
• 6.13. DeepUII Diagnostics
• 6.14. DNAe
• 6.15. Enzo Biochem
• 6.16. Eurofins Scientific
• 6.17. Fusion Genomics
• 6.18. GeneFluidics
• 6.19. Genetic Signatures
• 6.20. Great Basin Scientific, Inc
• 6.21. Hologic
• 6.22. Hutman Diagnostics
• 6.23. Inflammatix
• 6.24. Linear Diagnostics
• 6.25. Lumos Diagnostics
• 6.26. MGI
• 6.27. Millipore Sigma
• 6.28. OpGen
• 6.29. Pathogenomix
• 6.30. Qiagen
• 6.31. QuidelOrtho
• 6.32. Revvity
• 6.33. Roche Diagnostics
• 6.34. Scope Fluidics
• 6.35. SeLux Diagnostics
• 6.36. Sherlock Biosciences
• 6.37. Siemens Healthineers
• 6.38. Sysmex
• 6.39. Thermo Fisher Scientific
• 6.40. Uniogen
• 6.41. Vela Diagnostics
• 6.42. Visby Medical

7. The Global Market for Antimicrobial Resistance Diagnostics

• 7.1. Global Market Overview by Country
  • 7.1.1. Table - Global Market by Country
  • 7.1.2. Chart - Global Market by Country
• 7.2. Global Market by Technology - Overview
  • 7.2.1. Table - Global Market by Pathogen
  • 7.2.2. Chart - Global Market by Pathogen - Base/End Year Comparison
  • 7.2.3. Chart - Global Market by Pathogen - Base Year
  • 7.2.4. Chart - Global Market by Pathogen - End Year
  • 7.2.5. Chart - Global Market by Pathogen - Share by Year
  • 7.2.6. Chart - Global Market by Pathogen - Segment Growth
• 7.3. Global Market by Technology - Overview
  • 7.3.1. Table - Global Market by Technology
  • 7.3.2. Chart - Global Market by Technology - Base/End Year Comparison
  • 7.3.3. Chart - Global Market by Technology - Base Year
  • 7.3.4. Chart - Global Market by Technology - End Year
  • 7.3.5. Chart - Global Market by Technology - Share by Year
  • 7.3.6. Chart - Global Market by Technology - Segment Growth

8. Global Antibiotic Resistance Diagnostic Markets - By Pathogen

• 8.1. Drug Resistant Streptococcus Pneumoniae - DRSP
  • 8.1.1. Table DRSP - by Country
  • 8.1.2. Chart - DRSP Growth
• 8.2. Drug Resistant Campylobacter - DRC
  • 8.2.1. Table DRC - by Country
  • 8.2.2. Chart - DRC Growth
• 8.3. Clostridium Difficile - CD
  • 8.3.1. Table CD - by Country
  • 8.3.2. Chart - CD Growth
• 8.4. Methicillin Resistant Staphylococcus Aureus - MRSA
  • 8.4.1. Table MRSA - by Country
  • 8.4.2. Chart - MRSA Growth
• 8.5. Drug Resistant Neisseria Gonorrhoeae - DRNG
  • 8.5.1. Table DRNG - by Country
  • 8.5.2. Chart - DRNG Growth
• 8.6. Drug Resistant Salmonella - DRNTS
  • 8.6.1. Table DRNTS - by Country
  • 8.6.2. Chart - DRNTS Growth

9. Global Antibiotic Resistance Diagnostic Markets - by Technology

• 9.1. Microbiology Culture
  • 9.1.1. Table Culture - by Country
  • 9.1.2. Chart - Culture Growth
• 9.2. Immunoassay
  • 9.2.1. Table Immunoassay - by Country
  • 9.2.2. Chart - Immunoassay Growth
• 9.3. PCR
  • 9.3.1. Table PCR - by Country
  • 9.3.2. Chart - PCR Growth
• 9.4. NGS
  • 9.4.1. Table NGS - by Country
  • 9.4.2. Chart - NGS Growth
• 9.5. Mass Spectrometry - MS
  • 9.5.1. Table MS - by Country
  • 9.5.2. Chart - MS Growth
• 9.6. Rapid and Point of Care - Rapid/POC
  • 9.6.1. Table Rapid/POC - by Country
  • 9.6.2. Chart - Rapid/POC Growth

10. Vision of the Future of AMR Diagnostics

11. Appendices

• 11.1. United States Medicare System: Clinical Laboratory Fees Schedule

관련자료